QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
QQQ   444.74 (-0.02%)
AAPL   170.80 (-1.45%)
MSFT   421.11 (-0.08%)
META   489.33 (-0.92%)
GOOGL   150.54 (-0.22%)
AMZN   180.79 (+0.53%)
TSLA   177.68 (-1.20%)
NVDA   906.12 (+0.40%)
NIO   4.63 (-0.86%)
AMD   181.56 (+1.10%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.23 (+1.30%)
MU   118.36 (-0.65%)
CGC   9.29 (-2.72%)
GE   175.04 (-2.82%)
DIS   122.08 (+0.91%)
AMC   3.80 (-12.44%)
PFE   27.89 (+0.40%)
PYPL   67.14 (+0.86%)
XOM   115.66 (+0.60%)
NASDAQ:NCNA

NuCana (NCNA) Stock Price, News & Analysis

$0.26
-0.05 (-15.13%)
(As of 10:57 AM ET)
Today's Range
$0.23
$0.28
50-Day Range
$0.29
$0.42
52-Week Range
$0.23
$1.00
Volume
800,372 shs
Average Volume
1.64 million shs
Market Capitalization
$13.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

NuCana MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,501.0% Upside
$5.00 Price Target
Short Interest
Bearish
5.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of NuCana in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.42) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Medical Sector

495th out of 939 stocks

Pharmaceutical Preparations Industry

233rd out of 435 stocks

NCNA stock logo

About NuCana Stock (NASDAQ:NCNA)

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. The company applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing medicines, ProTides, to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil, which is in a Phase 1b/2 study in patients with metastatic colorectal cancer. The company also initiated a randomized Phase 2 study of NUC-3373, in combination with other agents, for the second-line treatment of patients with advanced colorectal cancer; and initiated a Phase 1b/2 modular study of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Its pipeline also comprises NUC-7738, a transformation of 3'-deoxyadenosine that is in the Phase 2 part of a Phase 1/2 study in patients with advanced solid tumors which is evaluating NUC-7738 as a monotherapy and in combination with pembrolizumab. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NCNA Stock Price History

NCNA Stock News Headlines

Short Interest in NuCana plc (NASDAQ:NCNA) Rises By 2,616.3%
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
NuCana Announces Plan to Implement ADS Ratio Change
Nucana (NCNA) Receives a Hold from TD Cowen
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
NuCana: Q4 Earnings Insights
Why NuCana Stock Is Up Today
Why Is NuCana (NCNA) Stock Up 102% Today?
NuCana: Potential Turnaround In 2024 But Risky
See More Headlines
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/17/2021
Today
3/28/2024
Next Earnings (Estimated)
5/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NCNA
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,501.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-34,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.35 per share

Miscellaneous

Free Float
35,978,000
Market Cap
$16.33 million
Optionable
Not Optionable
Beta
0.96
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Hugh Stephen Griffith (Age 56)
    Founder, CEO & Executive Director
    Comp: $1.29M
  • Mr. Donald Munoz (Age 55)
    Chief Financial Officer
  • Mr. David Harrison (Age 65)
    Head of Translational Medicine
  • Prof. Christopher B. Wood FRCS (Age 78)
    M.D., Ph.D., Chief Medical Officer
    Comp: $104.77k
  • Ms. Theresa Bruce
    Senior Vice President of Clinical Operations
  • Ms. Elisabeth Oelmann
    Senior Vice President of Medical & Clinical Development
  • Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 67)
    M.D., Chief Medical Officer
  • Martin Quinn
    Company Secretary

NCNA Stock Analysis - Frequently Asked Questions

Should I buy or sell NuCana stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings
or view top-rated stocks.

What is NuCana's stock price target for 2024?

2 Wall Street analysts have issued twelve-month target prices for NuCana's shares. Their NCNA share price targets range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 1,501.0% from the stock's current price.
View analysts price targets for NCNA
or view top-rated stocks among Wall Street analysts.

How have NCNA shares performed in 2024?

NuCana's stock was trading at $0.2958 on January 1st, 2024. Since then, NCNA shares have increased by 5.6% and is now trading at $0.3123.
View the best growth stocks for 2024 here
.

Are investors shorting NuCana?

NuCana saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,480,000 shares, an increase of 2,616.3% from the February 29th total of 91,300 shares. Based on an average daily volume of 1,560,000 shares, the days-to-cover ratio is presently 1.6 days. Approximately 5.7% of the shares of the company are sold short.
View NuCana's Short Interest
.

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024.
View our NCNA earnings forecast
.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) released its earnings results on Wednesday, November, 17th. The company reported ($15.00) EPS for the quarter, beating analysts' consensus estimates of ($18.50) by $3.50.

What other stocks do shareholders of NuCana own?
When did NuCana IPO?

NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager.

Who are NuCana's major shareholders?

NuCana's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.28%).

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NCNA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners